Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts

Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts

Upworthy

Published

UBS has downgraded Biogen Inc BIIB, noting inflection for its second Alzheimer’s drug Leqembi (lecanemab) will take longer than anticipated. Despite anticipating Leqembi’s continued dominance in the Mild Cognitive Impairment (MCI)/Mild Alzheimer’s market, recent reviews of IQVIA/Symphony data and…

#ubs #biogenincbiib #iqviasymphony #biogen #neutral #leqembi #fda #chrisviehbacher #biib

Full Article